The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://kathrynzxlw513076.blogs-service.com/70045231/glp-3-retatrutide-a-comparative-analysis